Re-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin inhibitors
Re-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin inhibitors
About this item
Full title
Author / Creator
Publisher
John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Background: Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) assessed the cardiovascular (CV) safety of sitagliptin versus placebo on CV outcomes in patients with type 2 diabetes and CV disease and found sitagliptin noninferior to placebo. Subsequently, based on feedback from FDA, the Sponsor of the trial, Merck & Co., Inc., engage...
Alternative Titles
Full title
Re-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin inhibitors
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_gale_infotracmisc_A740978334
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A740978334
Other Identifiers
ISSN
0160-9289
DOI
10.1002/clc.23844
